Summary

Report Overview
The Global Urological Cancer Drugs Market reached US$ 3.6 billion in 2023 and is expected to reach US$ 8.6 billion by 2031, growing at a CAGR of 11.9% during the forecast period 2024-2031.
Urological cancers affect the male and female urinary system's organs and structures and the male reproductive system. These cancers are fairly common. Types of urological cancers are, bladder cancer affects the cells that line the urinary bladder, a small sac containing urine for excretion. Renal cancer forms in the tiny tubes that clean the blood of the kidneys. Renal pelvic cancer is a rare form of this disease that occurs in the kidney that connects to the bladder. Testicular cancer forms in the testis and accounts for only one percent of all cancers in men. Urethral cancer occurs in the urethra, the tube that conducts urine from the bladder to the outside of the body. It is rare and occurs more often in men than in women.
Symptoms do not occur until the cancer has become more advanced. Blood in the urine (without pain) is a symptom of bladder, kidney, and prostate cancer—at later stages, pelvic and back pain can also develop. Patients with prostate cancer may also have other changes in urination and sexual function. Those with testicular or penile cancer notice a visible lesion on the skin, along with other skin changes or swelling. Any cancer patient can experience weight loss and fatigue.
Market Dynamics: Drivers
Increasing prevalence of urological cancers
The rising prevalence of urological cancers propels the market growth. For instance, according to an article published by the American Cancer Society, bladder cancer occurs mainly in older people. About 9 out of 10 people with this cancer are over the age of 55. The average age of people when they are diagnosed with bladder cancer is 73. Overall, the chance men will develop this cancer during their lifetime is about 1 in 28. For women, the chance is about 1 in 89.
In the UK, more than 52,000 men are diagnosed with prostate cancer every year on average, that is 144 men every day. More than 44,000 men are diagnosed with prostate cancer every year in England. More than 10,000 men die from prostate cancer every year in England. More than 3,800 men are diagnosed with prostate cancer every year in Scotland. More than 1,000 men die from prostate cancer every year in Scotland. More than 2,800 are diagnosed with prostate cancer every year in Wales. Around 630 men die from prostate cancer every year in Wales.
Restraints
Factors such as the high cost of chemotherapy and radiation therapy treatment are expected to hamper the market. The drugs that are used for chemotherapy and radiation therapy are very expensive and it is not affordable for all the people who are suffering from urological cancer.
Market Segment Analysis
The global urological cancer drugs market is segmented based on product, application, end-user, and region.
The segment prostate cancer accounted for approximately 56.8% of the global urological cancer drugs market share
The prostate cancer segment is expected to hold the largest market share over the forecast period. In this segment, technological advancements would drive this market.
Prostate cancer is the uncontrolled growth of cells in the prostate, a gland in the male reproductive system below the bladder. Abnormal growth of prostate tissue is usually detected through screening tests, typically blood tests that check for prostate-specific antigen (PSA) levels. Those with high levels of PSA in their blood are at increased risk for developing prostate cancer.
For instance, Lynparza (olaparib) was approved by the U.S. Food and Drug Administration (FDA) in May 2023, to treat BRCA-mutated metastatic castration-resistant prostate cancer (mCRPC). This approval makes Lynparza the first PARP inhibitor approved in combination with Zytiga (abiraterone) and a corticosteroid. Prostate cancer is the second-leading cause of cancer death in American men, behind only lung cancer. About 1 in 44 men will die of prostate cancer. There were 1,467,854 new cases of prostate cancer in 2022.
Market Geographical Share
North America accounted for approximately 41.6% of the global urological cancer drugs market share
North America region is expected to hold the largest market share over the forecast period. The rising incidence of urological cancers, and technological advancements in this region, help to propel the market.
For instance, according to an article published Centers for Disease Control and Prevention, based on the most recent data available, in the United States in 2022, 33,363 males died from prostate cancer. The rate of new cases of prostate cancer was 116.5 per 100,000 men per year. The death rate was 19.0 per 100,000 men per year. Approximately 12.8 percent of men will be diagnosed with prostate cancer at some point during their lifetime.
Kidney cancer is one of the 10 most common cancers in both men and women in the United States. It accounts for about 4% to 5% of all cancers. Overall, the lifetime risk for developing kidney cancer in men is about 1 in 43 (2.3%). The lifetime risk for women is about 1 in 73 (1.4%). In August 2024, based on the evidence from this randomized, active-controlled trial, belzutifan was approved by the U.S. Food and Drug Administration for adult patients with advanced renal cell carcinoma (RCC) following standard treatment with an ICI or anti-angiogenic therapy. This approval of a HIF-2α inhibitor meets a need for drugs with novel therapeutic mechanisms in advanced renal cell carcinoma.
Market Segmentation
By Product
Tablet
Enzalutamide
Abiraterone
Injection
Goserelin
Triptorelin Pamoate
Others
By Application
Prostate Cancer
Bladder Cancer
Kidney Cancer
Urethral Cancer
Others
By End-User
Hospitals
Specialty Clinics
Others
By Region
North America
U.S.
Canada
Mexico
Europe
Germany
U.K.
France
Spain
Italy
Rest of Europe
South America
Brazil
Argentina
Rest of South America
Asia-Pacific
China
India
Japan
South Korea
Rest of Asia-Pacific
Middle East and Africa
Market Competitive Landscape
The major global players in the global urological cancer drugs market include Novartis AG, Pfizer Inc., F. Hoffmann-La Roche Ltd., AstraZeneca, Johnson & Johnson Services, Inc., Astellas Pharma Inc., Bristol-Myers Squibb Company, Abbott, Sanofi, GlaxoSmithKline Plc., among others.
Key Developments
In April 2024, the U.S. Food and Drug Administration (FDA) approved the immunotherapy-boosting drug N-803, which is marketed under the brand name Anktiva, to be used in combination with the immunotherapy Bacillus Calmette-Guerin (BCG) for the treatment of patients with BCG-unresponsive non–muscle-invasive bladder cancer.
In January 2024, Pfizer’s oral poly ADP-ribose polymerase (PARP) inhibitor TALZENNA® (talazoparib), in combination with XTANDI® (enzalutamide) was approved for prostate cancer by the European Commission (EC)
Why Purchase the Report?
To visualize the global urological cancer drugs market segmentation based on product, application, end-user, and region as well as understand key commercial assets and players.
Identify commercial opportunities by analyzing trends and co-development
Excel data sheet with numerous data points of global urological cancer drugs market level with all segments.
PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
Product mapping is available in Excel consisting of key products of all the major players.
The global urological cancer drugs market report would provide approximately 51 tables, 54 figures, and 181 Pages.
Target Audience 2024
Manufacturers/ Buyers
Industry Investors/Investment Bankers
Research Professionals
Emerging Companies

ページTOPに戻る

Table of Contents

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Product
3.2. Snippet by Application
3.3. Snippet by End-User
3.4. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Increasing Prevalence of Urological Cancers
4.1.1.2. XX
4.1.2. Restraints
4.1.2.1. High Cost of Chemotherapy and Radiation Therapy
4.1.2.2. XX
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. Unmet Needs
5.6. PESTEL Analysis
5.7. Patent Analysis
5.8. SWOT Analysis
6. By Product
6.1. Introduction
6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
6.1.2. Market Attractiveness Index, By Product
6.2. Tablet*
6.2.1. Introduction
6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. Injection
6.4. Others
7. By Application
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
7.1.2. Market Attractiveness Index, By Application
7.2. Prostate Cancer*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Bladder Cancer
7.4. Kidney Cancer
7.5. Urethral Cancer
7.6. Others
8. By End-User
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
8.1.2. Market Attractiveness Index, By End-User
8.2. Hospitals*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Specialty Clinics
8.4. Others
9. By Region
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
9.1.2. Market Attractiveness Index, By Region
9.2. North America
9.2.1. Introduction
9.2.2. Key Region-Specific Dynamics
9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
9.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.2.6.1. U.S.
9.2.6.2. Canada
9.2.6.3. Mexico
9.3. Europe
9.3.1. Introduction
9.3.2. Key Region-Specific Dynamics
9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
9.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.3.6.1. Germany
9.3.6.2. UK
9.3.6.3. France
9.3.6.4. Italy
9.3.6.5. Spain
9.3.6.6. Rest of Europe
9.4. South America
9.4.1. Introduction
9.4.2. Key Region-Specific Dynamics
9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
9.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.4.6.1. Brazil
9.4.6.2. Argentina
9.4.6.3. Rest of South America
9.5. Asia-Pacific
9.5.1. Introduction
9.5.2. Key Region-Specific Dynamics
9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
9.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.5.6.1. China
9.5.6.2. India
9.5.6.3. Japan
9.5.6.4. South Korea
9.5.6.5. Rest of Asia-Pacific
9.6. Middle East and Africa
9.6.1. Introduction
9.6.2. Key Region-Specific Dynamics
9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
9.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
10. Competitive Landscape
10.1. Competitive Scenario
10.2. Market Positioning/Share Analysis
10.3. Mergers and Acquisitions Analysis
11. Company Profiles
11.1. Novartis AG *
11.1.1. Company Overview
11.1.2. Product Portfolio and Description
11.1.3. Financial Overview
11.1.4. Key Developments
11.2. Pfizer Inc.
11.3. F. Hoffmann-La Roche Ltd.
11.4. AstraZeneca
11.5. Johnson & Johnson Services Inc.
11.6. Astellas Pharma Inc.
11.7. Bristol-Myers Squibb Company
11.8. Abbott
11.9. Sanofi
11.10. GlaxoSmithKline Plc. (*LIST NOT EXHAUSTIVE)
12. Appendix
12.1. About Us and Services
12.2. Contact Us